Pregled bibliografske jedinice broj: 1259897
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group // International journal of cardiology, 365 (2022), 8-18 doi:10.1016/j.ijcard.2022.07.017 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1259897 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Translating results from the cardiovascular
outcomes trials with glucagon-like peptide-1
receptor agonists into clinical practice:
Recommendations from a Eastern and Southern Europe
diabetes expert group
Autori
Janez, Andrej ; Muzurovic, Emir ; Stoian, Anca Pantea ; Haluzik, Martin ; Guja, Cristian ; Czupryniak, Leszek ; Duvnjak, Lea ; Lalic, Nebojsa ; Tankova, Tsvetalina ; Bogdanski, Pawel ; Papanas, Nikolaos ; Nunes, Josè Silva ; Kempler, Peter ; Fras, Zlatko ; Rizzo, Manfredi
Izvornik
International journal of cardiology (0167-5273) 365
(2022);
8-18
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Algorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.
Sažetak
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE